According to the summary of the article, the duration of use of recalled generic valsartan was relatively short and probably did not pose an elevated risk of nitrosamine-induced cancer. However, patients exposed to these products for longer durations could have a potentially different risk of cancer.
Though nitrosamine exposure is not allowed, I think the effects should be evaluated correctly.